NIH R01 · 2025
Unraveling the neural mechanisms for satiety and weight loss by GLP1-based drugs
PROJECT SUMMARY Over the last several decades, obesity rates have been rising, and research has failed to solve this public health crisis. Now, we are at the precipice of change. Glucagon-like peptide-1 (GLP1)-based obesity drugs have emerged as a promising strategy for weight loss, and their unprecedented success is transforming the treatment of obesity. Despite their popularity, we have little understanding of the brain mechanisms that drive the food intake and body weight reduction from these drugs. In our preliminary studies, we found that hindbrain GLP1 receptor (GLP1R)-expressing neurons are necessary and sufficient for the effects of GLP1-based obesity drugs such as semaglutide…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.